In this study, doctors treated heart attack patients with their own bone marrow cells, selected for their healing potential and then reinjected into the heart, in an effort to improve the heart’s recovery. In the PreSERVE-AMI phase II trial, physicians from 60 sites treated 161 patients, making the study one of the largest to assess cell therapy for heart attacks in the United States. The study was sponsored by NeoStem, Inc.
Protocol for the PreSERVE-AMI trial, one of the largest studies of bone marrow cell therapy for heart attack in the United States. Researchers made real progress in determining the cell type and dose that can benefit patients.
Credit: Woodruff Health Sciences Center
Quyyumi is a member of NeoStem’s advisory board. This relationship has been reviewed and approved by Emory University School of Medicine.